


EXHIBIT L

Drugs@FDA: FDA Approved Drug Products

 [SHARE \(HTTPS://WWW.FACEBOOK.COM/SHARER/SHARER.PHP?U=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=020229\)](https://www.facebook.com/sharer/sharer.php?u=https://www.accessdata.fda.gov/scripts/cder/daif/index.cfm?event=overview.process&applno=020229)


 [TWEET \(HTTPS://TWITTER.COM/INTENT/TWEET/?TEXT=DRUGS@FDA: FDA APPROVED DRUG PRODUCTS&URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=020229\)](https://twitter.com/intent/tweet/?text=Drugs@FDA: FDA Approved Drug Products&url=https://www.accessdata.fda.gov/scripts/cder/daif/index.cfm?event=overview.process&applno=020229)



 [EMAIL \(MAILTO:?SUBJECT=DRUGS@FDA: FDA APPROVED DRUG PRODUCTS&BODY=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=020229\)](mailto:?subject=Drugs@FDA: FDA Approved Drug Products&body=https://www.accessdata.fda.gov/scripts/cder/daif/index.cfm?event=overview.process&applno=020229)

[Home \(index.cfm\)](#) | [Previous Page](#)

New Drug Application (NDA): 020229
 Company: JANSSEN PHARMS

 [EMAIL \(MAILTO:?SUBJECT=DRUGS@FDA: FDA APPROVED DRUG PRODUCTS&BODY=HTTP://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS%26VARAPPLNO=020229\)](mailto:?subject=Drugs@FDA: FDA Approved Drug Products&body=http://www.accessdata.fda.gov/scripts/cder/daif/index.cfm?event=overview.process%26varapplno=020229)

Products on NDA 020229



CSV Excel Print

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	R
LEUSTATIN	CLADRIBINE	1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	INJECTABLE;INJECTION	Discontinued	None	Yes	No

Showing 1 to 1 of 1 entries

Approval Date(s) and History, Letters, Labels, Reviews for NDA 020229**Original Approvals or Tentative Approvals**

CSV Excel Print

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes
02/26/1993	ORIG-1	Approval	Type 1 - New Molecular Entity	STANDARD		Withdrawn FR Effective 11/03/2016 Label is not available on this site.

Showing 1 to 1 of 1 entries

Supplements

CSV Excel Print

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert
08/02/2012	SUPPL-34		Label (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020/) Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/applletter/2012/)
06/29/2006	SUPPL-30		Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/applletter/2006/)

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert
08/22/2002	SUPPL-21		Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/applletter/2002/)
08/20/2002	SUPPL-7		Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/applletter/2002/)
08/20/2002	SUPPL-4		Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/applletter/2002/)

Showing 1 to 5 of 5 entries

[Labels for NDA 020229](#)

**LEUSTATIN[®] (cladribine)
Injection
For Intravenous Infusion Only**

WARNING

LEUSTATIN (cladribine) Injection should be administered under the supervision of a qualified physician experienced in the use of antineoplastic therapy. Suppression of bone marrow function should be anticipated. This is usually reversible and appears to be dose dependent. Serious neurological toxicity (including irreversible paraparesis and quadraparesis) has been reported in patients who received LEUSTATIN Injection by continuous infusion at high doses (4 to 9 times the recommended dose for Hairy Cell Leukemia). Neurologic toxicity appears to demonstrate a dose relationship; however, severe neurological toxicity has been reported rarely following treatment with standard cladribine dosing regimens.

Acute nephrotoxicity has been observed with high doses of LEUSTATIN (4 to 9 times the recommended dose for Hairy Cell Leukemia), especially when given concomitantly with other nephrotoxic agents/therapies.

DESCRIPTION

LEUSTATIN (cladribine) Injection (also commonly known as 2-chloro-2'-deoxy- β -D-adenosine) is a synthetic antineoplastic agent for continuous intravenous infusion. It is a clear, colorless, sterile, preservative-free, isotonic solution. LEUSTATIN Injection is available in single-use vials containing 10 mg (1 mg/mL) of cladribine, a chlorinated purine nucleoside analog. Each milliliter of LEUSTATIN Injection contains 1 mg of the active ingredient and 9 mg (0.15 mEq) of sodium chloride as an inactive ingredient. The solution has a pH range of 5.5 to 8.0. Phosphoric acid and/or dibasic sodium phosphate may have been added to adjust the pH to 6.3 ± 0.3 .

The chemical name for cladribine is 2-chloro-6-amino-9-(2-deoxy- β -D-erythropentofuranosyl) purine and the structure is represented below:

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.